Roundup: VUNO's at-home ECG device cleared in South Korea and more briefs
14 Oct 2022
Collaborate
Preview
Source: mobihealthnews
Credit: VUNO
VUNO scores government approval for at-home ECG device
Medical AI developer VUNO has received the approval of the Ministry of Food and Drug Safety (MFDS) for its at-home ECG device.
Called Hativ P30, the medical device not only provides a 6-lead heart signal measurement within 30 seconds, but it also analyses data to check for sinus rhythm, atrial fibrillation, bradycardia, and tachycardia.
The device is VUNO's second product release under its integrated health management brand, Hativ. Hativ Pro, its first personal ECG device, was awarded an MFDS certification in July.
Life insurer Max Life launches analytics solution for insurance underwriting
India-based Max Life Insurance Co. has developed and launched a health analytics solution for insurance underwriting.
Called MediCheck, the application uses digital health records from diagnostics centres to detect inaccurate medical reports in real time. It can also provide health scores of insurance customers.
The underwriting solution was developed to minimise the instance of claim repudiation and enable faster claims processing, said Max Life COO and director Manu Lavanya.
Samsung targets to screen 150,000 Indians for eye diseases using upcycled phones
Using upcycled phones, Samsung is targeting to screen about 150,000 individuals in India for eye diseases by the end of 2023.
The global technology manufacturer has been transforming old Galaxy devices into fundus cameras through its Galaxy Upcycling programme. The EYELIKE fundus cameras use AI to detect diseases in scanned retinal images.
The company has partnered with four eye hospitals – Sitapur Eye Hospital, Aravind Eye Hospital, Guruhasti Chikitsalya, and Dr Shroff’s Charity Eye Hospital – to set up eye care camps and use the upcycled devices to screen people for eye diseases.
Tags: VUNO, South Korea, Hativ, Hativ P30, ECG, Max Life Insurance, India, analytics, Samsung, Galaxy upcycling programme, EYELIKE fundus, eye disease, eye screening, AI
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.